Motor neuron diseases
Motor Neuron Diseases
Definition: Group of degenerative motor neuron diseases characterized by progressive muscle weakness and disability.
Causes: Mainly genetic.
Pathology & Causes
Muscle weakness and fatigue lead to disability.
Signs & Symptoms
General Symptoms:
History and physical examination reveal upper and lower motor neuron signs.
Muscle biopsy and electromyography (EMG) are essential diagnostics.
Diagnosis
Key Points:
Diagnosis relies on clinical history, physical examination, EMG results, and possibly muscle biopsy.
Tests confirm motor neuron disease, indicating both upper and lower motor neuron involvement.
Amyotrophic Lateral Sclerosis (ALS)
Overview:
ALS is a progressive, degenerative motor neuron disease known as Lou Gehrig’s disease.
Genetic associations in familial ALS provide insights into its pathogenesis.
Pathology & Causes
Mechanisms of Injury:
Protein aggregation leads to neuronal injury and death.
Mutations in SOD1 (20% of familial ALS) lead to misfolding, causing neuronal injury and protein aggregation.
C9orf72 mutation accounts for 40% of familial cases, signaling an unknown significance in ALS.
Signs & Symptoms
Early Symptoms:
Asymmetric hand weakness, dropping objects, and cramping in upper extremities.
Dysarthria, dysphagia, and dysphonia develop later.
Late Symptoms:
Respiratory weakness introducing dyspnea and infections like pneumonia.
Diagnosis
Laboratory Findings:
Elevated creatinine kinase due to muscle atrophy.
Diagnostic Criteria (El Escorial):
Evidence of lower and upper motor neuron disease.
Progressive spread of signs/symptoms based on clinical findings.
Treatments
Medications:
Disease-modifying agents have limited efficacy.
Riluzole reduces excitotoxicity from glutamate, slowing neuron degeneration.
Edaravone acts as a free radical scavenger to decrease oxidative stress.
Supportive Care:
Multidisciplinary approach for symptom management, respiratory care, and regular evaluations.
Spinal Muscular Atrophy (SMA)
Overview:
Genetic degenerative neurological disease primarily affecting children, characterized by lower motor neuron weakness and muscular atrophy.
Causes:
Loss-of-function mutation in the SMN1 gene leads to reduced motor neuron survival and degeneration of anterior horn cells.
Pathology:
Mutations lead to poor production of sufficient SMN protein, attributing to motor neuron death.
Symptoms & Diagnosis
Signs:
Common signs include proximal limb weakness, reduced muscle strength, hypotonia, and fasciculations.
Diagnostics:
EMG and muscle biopsies reveal characteristic abnormalities in muscle fiber size and activity.
Treatment
Medications:
Nusinersen, an experimental therapy, modifies mRNA splicing to increase functional SMN protein levels.
Supportive Interventions:
Focus on pulmonary care, nutritional management, and physical therapy to promote mobility and manage complications.
Types of Spinal Muscular Atrophy
Classification:
Type 0: Prenatal onset with severe congenital defects.
Type 1: Onset in infancy with a poor prognosis.
Type 2: Onset between 6-18 months with better outcomes.
Type 3: Adolescent onset with variable symptom severity.
Type 4: Adult-onset with mild symptoms.